Muhammad Abdul-Ghani MD, PhDProfessor of Medicine, Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, Texas
Muhammad Abdul-Ghani, MD, PhD, is Professor of Medicine in the Diabetes Division at UT Health San Antonio. His major interests focus on the pathophysiology and treatment of type 2 diabetes and prediabetes. He has played a pivotal role in defining the mechanism of action of SGLT2 inhibitors and GLP-1 receptor agonists and their combined effect on muscle/hepatic insulin sensitivity and beta cell function. His research has delineated the distinct pathophysiologic disturbances present in individuals with IGT and IFG and the superiority of the one hour plasma glucose concentration in identifying individuals at risk for future development of diabetes. He also has been a pioneer in advocating combination therapy with agents that correct specific pathophysiologic defects present in the prediabetic/diabetic state and this work has been funded by the NIDDK/NIH.
DisclosuresDr. Abdul-Ghani has no relevant disclosures.
Recent Contributions to PracticeUpdate:
- Effects of Dapagliflozin on Myocardial Function and Metabolism in Type 2 Diabetes
- Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction
- Benefit of Pioglitazone on CVD and Non-Alcoholic Steatohepatitis vs Low Risk of Bladder Cancer
- Association of Glucose Patterns During an OGTT With Risk of Diabetes, Cardiovascular Disease, and Mortality